Organogenesis Holdings Inc. ORGO
We take great care to ensure that the data presented and summarized in this overview for Organogenesis Holdings Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ORGO
View all-
Soleus Capital Management, L.P. Greenwich, CT12.5MShares$62.9 Million2.78% of portfolio
-
Morgan Stanley New York, NY11.8MShares$59.6 Million0.0% of portfolio
-
Black Rock Inc. New York, NY5.09MShares$25.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.59MShares$18.1 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA3.08MShares$15.5 Million0.03% of portfolio
-
Assenagon Asset Management S.A.2.95MShares$14.9 Million0.02% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.79MShares$14.1 Million0.0% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M2.45MShares$12.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.74MShares$8.76 Million0.0% of portfolio
-
State Street Corp Boston, MA1.55MShares$7.83 Million0.0% of portfolio
Latest Institutional Activity in ORGO
Top Purchases
Top Sells
About ORGO
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Insider Transactions at ORGO
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 01
2025
|
Robert Cavorsi Vice President, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
667
-0.35%
|
$4,002
$6.21 P/Share
|
Feb 19
2025
|
Robert Cavorsi Vice President, Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
61,705
+24.47%
|
-
|
Feb 19
2025
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,156
+22.8%
|
-
|
Feb 19
2025
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,047
+21.43%
|
-
|
Feb 19
2025
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
183,067
+21.45%
|
-
|
Feb 19
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
42,493
+17.77%
|
-
|
Feb 19
2025
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
184,136
+16.25%
|
-
|
Feb 19
2025
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+17.29%
|
-
|
Feb 19
2025
|
Garrett Lustig Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+39.19%
|
-
|
Feb 19
2025
|
Gilberto Quintero Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.67%
|
-
|
Feb 19
2025
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.5%
|
-
|
Feb 19
2025
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
708,215
+16.77%
|
-
|
Feb 19
2025
|
Michele Ilene Korfin Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.67%
|
-
|
Feb 19
2025
|
Michael Joseph Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.53%
|
-
|
Feb 19
2025
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.01%
|
-
|
Feb 16
2025
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,123
-0.22%
|
$18,369
$3.7 P/Share
|
Feb 16
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-0.46%
|
$2,157
$3.7 P/Share
|
Feb 16
2025
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-0.2%
|
$2,412
$3.7 P/Share
|
Feb 16
2025
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
646
-0.15%
|
$1,938
$3.7 P/Share
|
Feb 16
2025
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-0.1%
|
$2,370
$3.7 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 1.85M shares |
---|---|
Exercise of conversion of derivative security | 1.22M shares |
Bona fide gift | 32.4M shares |
Payment of exercise price or tax liability | 426K shares |
---|---|
Open market or private sale | 380K shares |
Sale (or disposition) back to the issuer | 14.2M shares |
Other acquisition or disposition | 1.63M shares |
Bona fide gift | 16.2M shares |